跳至主要内容
临床试验/NCT01645761
NCT01645761已完成不适用

Additive Effect of Endonase on Eradication Rate of the 7-day Standard Proton Pump Inhibitor-based Triple Therapy for Helicobacter Pylori

Chuncheon Sacred Heart Hospital1 个研究点 分布在 1 个国家目标入组 112 人开始时间: 2012年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
112
试验地点
1
主要终点
Eradication rate

研究概览

简要总结

Endonase, a kind of protease, is known to cause both extensive degradation of mucins and a reduction in mucus viscosity. As part of the search for more effective forms of therapy against H. pylori when it colonizes not only the surface of the surface mucosal cells but also the surface mucous gel layer covering the mucosal surface of the stomach. The investigators decided to investigate whether or not endonase might have additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or Female with 18 years or more of age without history of H. pylori eradication AND
  • Patients with H. pylori associated peptic ulcer in scar stage, OR
  • Non-ulcer dyspepsia patients with H. pylori infection

排除标准

  • Under 18 years, OR
  • Patients with a history of previous treatment of H. pylori infection, OR
  • Pregnant or Breast feeding women, OR
  • Patients with severe renal, liver, or heart disease, OR
  • Patients with gastric malignancy, OR
  • Patients with a history of drug allergy or hypersensitivity, OR
  • Patients who had received treatment with antibiotics or proton pump inhibitors, H2 Blocker, Bismuth preparation, Anticoagulant, Ketoconazole, Glucocorticoid during the 2 weeks preceding endoscopy

研究组 & 干预措施

PPI-based triple therapy with endonase

Experimental

7-day standard proton pump inhibitor-based triple therapy (the standard dosage of PPI, 1,000 mg of amoxicillin and 500 mg of clindamycin twice daily for one week) plus 20,000 units of endonase twice daily for one week.

干预措施: Endonase (Drug)

结局指标

主要结局

Eradication rate

时间窗: 4 weeks

Intention-to-treat analysis and per-protocol analysis to compare the eradication rate of the 7-day standard PPI-based triple therapy plus endonase with that of the 7-day standard PPI-based triple therapy

次要结局

  • Number of participants taking over 85% of medicine(4 weeks)
  • Number of participants with adverse events(4 weeks)

研究者

发起方
Chuncheon Sacred Heart Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Yeonsoo Kim

Assistant Professor

Chuncheon Sacred Heart Hospital

研究点 (1)

Loading locations...

相似试验